Literature DB >> 2164438

Predictors of 5-year survival and curability in small cell lung cancer.

J P Crown1, A P Chahinian, I S Jaffrey, O J Glidewell, M Kaneko, J F Holland.   

Abstract

A retrospective analysis of various characteristics in 81 small cell lung cancer patients treated at the Mount Sinai Medical Center, New York, from 1974 to 1982 was carried out to identify factors which had prognostic significance for long-term survival, defined as actual disease-free survival for at least 5 years from initiation of therapy. Six patients, five female patients (16.7%) and one male patient (2%), including four limited disease (9.7%) and two extensive disease patients (5%) were long-term survivors (73 to 96+ months from onset of therapy), and among them three remain alive and disease-free at 84, 84, and 96 months from first treatment, respectively. Although several factors, including sex, stage of disease (limited versus extensive), and occurrence of herpes zoster predicted overall survival duration, female sex and an occurrence of herpes zoster were the only variables which were statistically significantly related to 5-year survival. Herpes zoster was a relatively late occurrence whereas female sex was an independent positive prognostic factor.

Entities:  

Mesh:

Year:  1990        PMID: 2164438     DOI: 10.1002/1097-0142(19900715)66:2<382::aid-cncr2820660231>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Physiological changes due to age. Implications for respiratory drug therapy.

Authors:  J F Morris
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

2.  Prognostic factors for survival in terminal lung cancer patients.

Authors:  R S Schonwetter; B E Robinson; G Ramirez
Journal:  J Gen Intern Med       Date:  1994-07       Impact factor: 5.128

3.  Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.

Authors:  Sarah Sharman Moser; Jair Bar; Inna Kan; Keren Ofek; Raanan Cohen; Nikhil Khandelwal; Varda Shalev; Gabriel Chodick; Nava Siegelmann-Danieli
Journal:  Curr Oncol       Date:  2021-01-08       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.